Information  X 
Enter a valid email address
  Print      Mail a friend       More announcements

Tuesday 31 March, 2020

Societe Generale SA

Form 8.3 - Allergan plc

RNS Number : 2424I
Societe Generale SA
31 March 2020
 

  Ap19

 

 

FORM   8.3

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

 

1.  KEY   INFORMATION

 

Nameofpersondealing (Note 1)

Société Générale S.A.

Companydealtin

   Allergan plc

Classofrelevantsecuritytowhichthe dealingsbeingdisclosedrelate (Note 2)

US$0.0001 ordinary shares

Date of dealing

30/03/2020

 

2.  INTERESTS AND SHORT POSITIONS

 

(a)  Interests   and   short   positions   (following   dealing)   in   the   class   of   relevant   security   dealt   in   (Note   3)

 

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

1,820,060

0.55

50,043

0.02

(2) Derivatives (other than options)

0

0.00

1,394,127

0.42

(3) Options and agreements to purchase/sell

58,500

0.02

0

0.00

Total

*5,254,210

*1.60

1,444,170

0.44

 

* Include the holding of 3,375,650 shares on borrow products

 

 

 

(b)  Interests and short positions in relevant securities of the company, other than the class dealt in  (Note   3)

Class of relevant security:

Long

Short

 

Number

(%)

Number

(%)

(1) Relevant securities

 

 

 

 

(2) Derivatives (other than options)

 

 

 

 

(3) Options and agreements to purchase/sell

 

 

 

 

Total

 

 

 

 

Ap20

 

 

1.  DEALINGS  (Note   4)

 

(a)  Purchases and sales

Purchase/sale

Number of relevant securities

Price per unit USD (Note 5)

Purchase

100

176.06

Purchase

100

175.95

Purchase

23

175.18

Purchase

100

175.8

Purchase

100

176.47

Purchase

38

175.35

Purchase

100

176.09

Purchase

100

176.34

Purchase

100

176.36

Purchase

34

176.38

Purchase

66

176.38

Purchase

10

175.66

Purchase

90

175.66

Purchase

85

175.94

Purchase

15

175.94

Purchase

12

176.09

Purchase

88

176.09

Purchase

32

176.07

Purchase

100

176.12

Purchase

100

176.05

Purchase

90

175.79

Purchase

10

175.79

Purchase

6

176.06

Purchase

94

176.06

Purchase

100

175.73

Purchase

8

176.07

Purchase

266

175.811015

Purchase

100

176.07

Purchase

100

176.07

Purchase

113

176.085398

Purchase

100

176.53

Purchase

1,855

176.31

Purchase

50

176.02

Purchase

50

176

Purchase

3,152

176.31

Purchase

200

176.31

Purchase

8,831

176.24787

Purchase

3,000

175.27171

Purchase

788

176.31

Purchase

1,582

176.31

Purchase

275

175.8426

Purchase

73

176.31

Sale

61

175.87

Sale

38

175.17

Sale

100

176.31

Sale

62

176.58

Sale

38

176.58

Sale

75

176.04

Sale

81

176.32

Sale

40

176.52

Sale

100

176.52

Sale

113

175.85685

Sale

1,090

176.266404

Sale

100

175.9

Sale

100

175.29

Sale

100

175.6

Sale

100

175.95

Sale

100

176.09

Sale

100

176.32

Sale

40

175.29

Sale

100

176.23

Sale

100

175.29

Sale

29

176.35

Sale

100

176.26

Sale

100

176.26

Sale

99

176.11

Sale

1

176.11

Sale

100

175.36

Sale

100

176.58

Sale

100

176.48

Sale

100

176.26

Sale

100

175.79

Sale

100

175.89

Sale

20

175.88

Sale

80

175.88

Sale

100

177.2

Sale

100

175.29

Sale

100

175.44

Sale

202

176.510644

Sale

100

175.44

Sale

156

176.31

Sale

100

176.09

Sale

25

176.96

Sale

198

174.64

Sale

28

176.31

Sale

200

176.31

Sale

1,655

176.31

Total Purchases

22,236

 

Total Sales

6,631

 

 

 

(b)  Derivatives transactions (other than options transactions)

 

Productname,

e.g. CFD

Natureoftransaction

(Note 6)

Numberofrelevantsecurities

(Note 7)

Priceperunit USD

(Note 5)

CFD

Increased short

8,831

176.2479

 

(c)  Options transactions in respect of existing relevant securities

 

 

(i)  Writing, selling, purchasing or varying

 

Productname,

e.g. call option

Writing, selling,purchasing,varyingetc.

Numberofsecurities towhichtheoptionrelates (Note 7)

Exercise price

Type, e.g.American,Europeanetc.

Expiry date

Optionmoney paid/receivedperunit (Note 5)

 

 

 

 

 

 

 

 

 

(ii)  Exercising

 

Productname,

e.g. call option

Numberofsecurities

Exercisepriceper unit (Note 5)

 

 

 

 

 

(d)  Other dealings (including transactions in respect of new securities) (Note 4)

 

Nature of transaction

(Note 8)

Details

Price per unit

(if applicable) (Note 5)

 

 

 

 

Ap21

2.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

 

 

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

 

 

 

 

Is a Supplemental Form 8 attached?  (Note   9)     Yes

 

Dateofdisclosure

31/03/2020

Contact name

Société Générale - Disclosure team

Telephone number

+33 1 42 14 92 74

If aconnectedEFM,nameofofferee/offerorwithwhichconnected

 

If aconnectedEFM,statenatureofconnection (Note 10)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Ap23

 

SUPPLEMENTAL   FORM 8

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 8.1 AND RULE 8.3 OF THE IRISH TAKEOVER PANEL 

ACT,   1997, TAKEOVER RULES, 2013

 

 

 

 

DETAILS   OF OPEN POSITIONS

 

(This   form   should   be   attached   to   Form   8.1(a)   & (b)(i), Form 8.1(b)(ii) or Form 8.3, as appropriate)

 

OPEN POSITIONS  (Note   1)

 

 

 

Productname,

e.g. call option

Written, orpurchased

Numberofrelevant securitiestowhichtheoptionorderivativerelates

Exercise price (Note 2)

Type, e.g.American,Europeanetc.

Expiry date

Listed Put Option

Sale

40,000

175

American options

15/01/2021

Listed Put Option

Sale

18,500

190

American options

15/01/2021

 

 

Notes

 

1.  Where there are open option positions or open derivative positions (except for CFDs), full details should be given. Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2.  For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rule 8 of the  

Rules. If in doubt, consult the Panel.

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISESDFFFFESSEED

a d v e r t i s e m e n t